IRIS
DE ANGELIS, CARMINE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.006
NA - Nord America 2.768
EU - Europa 2.352
SA - Sud America 518
AF - Africa 89
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 9.738
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.639
SG - Singapore 1.775
RU - Federazione Russa 1.106
CN - Cina 778
VN - Vietnam 702
IT - Italia 528
BR - Brasile 416
HK - Hong Kong 330
DE - Germania 177
FR - Francia 119
NL - Olanda 103
IN - India 101
JP - Giappone 78
GB - Regno Unito 76
CA - Canada 66
KR - Corea 52
FI - Finlandia 50
AR - Argentina 44
MX - Messico 36
IE - Irlanda 32
UA - Ucraina 27
IQ - Iraq 26
ZA - Sudafrica 25
CI - Costa d'Avorio 22
ES - Italia 22
PK - Pakistan 22
BD - Bangladesh 20
EC - Ecuador 18
PH - Filippine 18
PL - Polonia 18
SE - Svezia 18
AT - Austria 17
ID - Indonesia 13
TH - Thailandia 12
VE - Venezuela 12
LT - Lituania 11
CO - Colombia 10
TW - Taiwan 10
UZ - Uzbekistan 10
TR - Turchia 9
NP - Nepal 8
JM - Giamaica 7
MA - Marocco 7
PY - Paraguay 7
TN - Tunisia 7
EG - Egitto 6
PT - Portogallo 6
SA - Arabia Saudita 6
CZ - Repubblica Ceca 5
IL - Israele 5
AE - Emirati Arabi Uniti 4
CL - Cile 4
DZ - Algeria 4
GT - Guatemala 4
LV - Lettonia 4
MY - Malesia 4
RS - Serbia 4
AZ - Azerbaigian 3
BY - Bielorussia 3
BZ - Belize 3
GE - Georgia 3
NO - Norvegia 3
PE - Perù 3
SY - Repubblica araba siriana 3
AL - Albania 2
BE - Belgio 2
BF - Burkina Faso 2
BO - Bolivia 2
CY - Cipro 2
DK - Danimarca 2
DM - Dominica 2
ET - Etiopia 2
GR - Grecia 2
HN - Honduras 2
HR - Croazia 2
JO - Giordania 2
KE - Kenya 2
MK - Macedonia 2
NG - Nigeria 2
NZ - Nuova Zelanda 2
OM - Oman 2
PA - Panama 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
ZM - Zambia 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
BG - Bulgaria 1
BS - Bahamas 1
CH - Svizzera 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DO - Repubblica Dominicana 1
EE - Estonia 1
IR - Iran 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LI - Liechtenstein 1
Totale 9.718
Salva come PNG Salva come JPEG
Città #
Singapore 931
San Jose 420
Hong Kong 321
Moscow 259
Hefei 252
Ashburn 222
Ho Chi Minh City 197
Beijing 196
Chandler 189
Hanoi 156
Naples 137
Santa Clara 111
The Dalles 88
Dallas 87
Amsterdam 82
Lauterbourg 80
Los Angeles 68
Millbury 65
Tokyo 60
New York 49
Lawrence 46
Kochi 44
Seoul 42
Redondo Beach 41
Des Moines 39
Munich 39
São Paulo 38
Buffalo 35
Haiphong 35
Boston 34
Council Bluffs 34
Napoli 34
Milan 32
Nuremberg 31
Dearborn 30
Da Nang 27
Dong Ket 26
London 21
Orem 21
Wilmington 21
Montreal 20
Turku 19
Nanjing 18
Rome 18
Warsaw 18
Chicago 17
Denver 17
Princeton 17
Houston 16
Mexico City 16
Ottawa 16
Seattle 16
Pune 15
Frankfurt am Main 14
Lappeenranta 14
Rio de Janeiro 13
Stockholm 13
Belo Horizonte 12
Brooklyn 11
Johannesburg 11
Kagoya 10
Quito 10
Salvador 10
Atlanta 9
Biên Hòa 9
Brasília 9
Curitiba 9
Erbil 9
Manchester 9
Ninh Bình 9
Toronto 9
Dhaka 8
Hải Dương 8
Jacksonville 8
Tashkent 8
Wuhan 8
Buenos Aires 7
Bắc Ninh 7
Dublin 7
Guangzhou 7
Phoenix 7
Pomigliano d'Arco 7
Shanghai 7
Thái Nguyên 7
Tân Tiến 7
Vienna 7
Asunción 6
Casoria 6
Chennai 6
Fairfield 6
Formia 6
Guayaquil 6
Hebei 6
Krefeld 6
Porto Alegre 6
Praia Grande 6
Salt Lake City 6
Tianjin 6
Boardman 5
Borgomanero 5
Totale 5.245
Salva come PNG Salva come JPEG
Nome #
Impaired Seroconversion After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA Vaccine in Patients With Thymic Epithelial Tumors 196
Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy 171
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 162
Prevalence of Sarcopenia in Women with Breast Cancer 161
Combined effect of obesity and diabetes on early breast cancer outcome: A prospective observational study 154
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 152
Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era 150
Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series 150
Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study 149
Tumor characteristics and prognosis in familial breast cancer 148
Safety and immunogenicity of the COVID-19 vaccine BNT162b2 for patients with breast and gynecological cancer on active anticancer therapy: Results of a prospective observational study 145
Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study 145
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 141
Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy 138
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 135
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis 134
Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI) 134
In-house homologous recombination deficiency testing in ovarian cancer: a multi-institutional Italian pilot study 133
Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis 132
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 131
Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type 130
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 129
Circulating tumor cell investigation in breast cancer patient-derived xenograft models by automated immunofluorescence staining, image acquisition, and single cell retrieval and analysis 129
Breast cancer prognosis in BRCA1/2 mutation carriers: A case control study. 127
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 127
How SARS-CoV-2 Infection Impacts the Management of Patients with Vulvar Cancer: Experience in a Third-Level Hospital of Southern Italy 126
Central obesity, body mass index, metabolic syndrome and mortality in Mediterranean breast cancer patients 126
The Epithelial-Stromal Interaction as a Potential Target for Breast Cancer Treatment 126
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 122
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer 122
GMO-Gestione Malattie Oncologiche in Regione Campania. 121
Immune Response Against Head and Neck Cancer: Biological Mechanisms and Implication on Therapy 121
Brca1/2 ngs somatic testing in clinical practice: a short report 121
Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie 117
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories 116
ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer 116
Corrigendum to 'Eribulin in combination with bevacizumab as second-line treatment for HER2-negative metastatic breast cancer progressing after first-line therapy with paclitaxel and bevacizumab: a multicenter, phase II, single arm trial (GIM11-BERGI)': [ESMO Open Volume 6, Issue 2, April 2021, 100054] 113
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 112
Blockade of AP-1 potentiates endocrine therapy and overcomes resistance 110
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studies 109
Neoadjuvant Versus Adjuvant Systemic Therapy in Breast Cancer: A Matched Case-control Study 107
miRNAs in the Box: Potential Diagnostic Role for Extracellular Vesicle-Packaged miRNA-27a and miRNA-128 in Breast Cancer 107
Activation of the IFN signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer 104
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer 103
A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer 103
Triple-negative breast cancers: Biomarkers and outcomes 102
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance 102
MITO END-3: efficacy of avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy 101
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 99
Neratinib in HER2-Positive Breast Cancer Patients 97
Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance 97
Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. 96
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer 96
Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis 94
Ribociclib in newly diagnosed hepatitis B infection: A case report 93
Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with Anti-HER2 therapy 93
PTK6 regulates growth and survival of endocrine therapyresistant ER+ breast cancer cells 93
Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review 92
Ribociclib in HR+/HER2− Advanced or Metastatic Breast Cancer Patients 92
HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer 91
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 vs. 24 Weeks in Patients with HER2-positive Breast Cancer 90
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer 88
FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer 85
NPY1R exerts inhibitory action on estradiol-stimulated growth and predicts endocrine sensitivity and better survival in ER-positive breast cancer 85
Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment 85
Imaging tests in staging and surveillance of non-metastatic breast cancer: changes in routine clinical practice and cost implications 84
Analysis of circulating extracellular vesicle derived microRNAs in breast cancer patients with obesity: a potential role for Let-7a 82
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 80
Nab-paclitaxel for the management of triple-negative metastatic breast cancer: a case study 79
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer 78
Molecular mechanism and clinical implications of endocrine therapy resistance in breast cancer. 76
GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer 76
Evaluation of the predictive role of tumor immune infiltrate in HER2-positive breast cancer patients treated with neoadjuvant anti-HER2 therapy without chemotherapy 74
Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer 74
Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up. 73
A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer 70
Unlocking the potential of Molecular Tumor Boards: from cutting-edge data interpretation to innovative clinical pathways 69
A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer 69
Towards personalized treatment for early stage HER2-positive breast cancer 69
Intermediate clinical endpoints in early-stage breast cancer: an analysis of individual patient data from the Gruppo Italiano Mammella and Mammella Intergruppo trials 68
Molecular mechanisms of endocrine resistance 68
Evolving treatments and outcomes in HER2-Positive metastatic breast cancer: Data from the GIM14/BIOMETA study 67
Tamoxifen resistance in breast cancer is regulated by the EZH2–ERa–GREB1 transcriptional axis 67
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models 65
De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance 64
Embryonic transcription factor SOX9 drives breast cancer endocrine resistance 63
The changing role of ER in endocrine resistance 62
Targeting the Mevalonate Pathway to Overcome Acquired Anti-HER2 Treatment Resistance in Breast Cancer 62
The Evolving Role of the Estrogen Receptor Mutations in Endocrine Therapy-Resistant Breast Cancer 59
Resistance to Anti-HER2 Therapies in Breast Cancer 57
Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation 57
Interferon Signaling in Estrogen Receptor-positive Breast Cancer: A Revitalized Topic 57
Extended Adjuvant Endocrine Treatment in Luminal Breast Cancers in the Era of Genomic Tests 55
Low PETN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer 53
Estrogen-induced transcription at individual alleles is independent of receptor level and active conformation but can be modulated by coactivators activity. 48
Increased lysosomal biomass is responsible for the resistance of triple-negative breast cancers to CDK4/6 inhibition 43
What medical oncologist residents think about the Italian speciality schools: A survey of the Italian Association of Medical Oncology (AIOM) on educational, clinical and research activities 43
Editorial: Molecular predictive pathology in gynecologic malignancies 37
PIK3CA testing in HR+/HER2− metastatic breast cancer: assessing pathology laboratories capacity and needs 8
Impact of relative dose intensity of first-line platinum-based chemotherapy in patients with thymic epithelial tumors: a retrospective study 3
Totale 9.935
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.878
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.878
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202144 0 0 0 0 0 0 0 0 0 0 12 32
2021/2022410 7 1 61 1 6 14 11 14 37 32 95 131
2022/2023568 66 36 21 30 57 56 15 52 69 96 53 17
2023/2024478 15 70 59 28 22 53 10 41 17 19 97 47
2024/20252.807 136 167 7 71 58 145 341 173 184 373 922 230
2025/20265.214 537 480 587 568 894 252 480 332 603 356 125 0
Totale 9.935